On July 28, the U.S. Food and Drug Administration (FDA) approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years. Read more at here.
FDA approves new drug for severe drooling
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
